Economy/Home · Economy

Hanmi Pharm Emphasizes Safe Use of 'Effe' After Approval... GLP-1 Obesity Treatment Results and Monday's Stock Variables

Hanmi Pharmaceutical is emphasizing the importance of patient safety and appropriate prescribing for its GLP-1 obesity treatment 'Effe (ingredient name: epeglanatide)' following its domestic product approval in Korea. Attention is also focused on the stock's price movement in the market on Monday, t

Wooil Shim
Staff Reporter
8 min read
Hanmi Pharm Emphasizes Safe Use of 'Effe' After Approval... GLP-1 Obesity Treatment Results and Monday's Stock Variables
CBC News

Hanmi Pharmaceutical is emphasizing the importance of patient safety and appropriate prescribing for its GLP-1 obesity treatment 'Effe (ingredient name: epeglanatide)' following its domestic product approval in Korea. Attention is also focused on the stock's price movement in the market on Monday, the 19th. While the obesity treatment development achievements have drawn investor interest, the product's commercialization potential and its future contribution to earnings are expected to serve as key judgment factors in actual market evaluation.

■ "Prescription Through Medical Consultation Needed"... Safe Use Guidance

On the 12th, Hanmi Pharmaceutical posted guidance on the safe use of prescription drugs on its official website. The company explained that it manages its pharmaceuticals in accordance with relevant regulations and approval terms, and provides accurate product information to healthcare professionals.

In particular, with interest in obesity treatments expanding following Effe's product approval, the company stressed the need for patients to fully understand the drug's characteristics and receive treatment through consultation with medical staff. GLP-1 obesity treatments must be prescribed taking into account individual health conditions, underlying diseases, and concomitant medications. Hanmi Pharmaceutical guided users to check detailed product information on its official website and recommended that actual decisions on administration be made in consultation with healthcare professionals.

■ LAPSCOVERY Applied... Average 9.75% Weight Loss in Phase 3 Trial

Effe is an obesity treatment applying LAPSCOVERY, Hanmi Pharmaceutical's proprietary long-acting drug platform. The company stated that in a 40-week interim analysis of the Phase 3 trial conducted on 448 Korean obesity patients, an average weight loss of 9.75% was observed.

Production is also carried out domestically. Hanmi Pharmaceutical explained that it has established a system producing everything from raw materials to finished products at its Pyeongtaek Bio Plant. Through this, the company aims to secure stable drug supply and respond to future product demand.

■ Approval Does Not Equal Revenue... Key Points to Watch for the 19th's Stock Price

However, product approval and clinical results do not directly guarantee expanded revenue. Actual prescription growth and market establishment may vary depending on multiple factors such as product supply, pricing, and choices by doctors and patients.

The stock has also shown volatility amid mixed evaluations of expectations and profitability surrounding Effe's market entry. Given the sharp short-term decline, it is necessary to watch both whether additional buying flows in and the possibility of profit-taking sell orders emerging. In particular, how much Effe's supply price contributes to actual prescription expansion and how it affects initial sales volume and profitability could be important variables in evaluating the company's future value.

However, the rise on the 16th alone makes it difficult to judge that the stock has recovered its trend. In Monday's trading on the 19th, rather than whether the price rises or falls early in the session, attention is on trading volume, the persistence of buying pressure, and price movements around the previous close of 397,500 won.

While Hanmi Pharmaceutical emphasizes the safe use of its drug, the stock market is expected to continue seeking to confirm actual business performance following Effe's launch.

[This article does not recommend buying or selling any specific stock. Stock prices may vary depending on corporate performance and market conditions, and future trends cannot be guaranteed. Investment decisions and the responsibility thereof lie with the investor. Whether to use the medication should be decided in consultation with medical professionals. AI assistance was used in writing this article.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.